Somerville Biosafety Committee Approves Gene Therapy Startup With Five Conditions

Other Committee · Meeting of April 16, 2026

Somerville Biosafety Committee conditionally approved a biosafety permit for gene therapy startup Solubritas Therapeutics. The committee voted 5-0 at its April 16 remote meeting to grant the permit to the six-employee company, which is subletting 2,500 square feet of biosafety level 2 lab space at 101 South Street and plans to grow to roughly 12 staff by mid-2026. The company uses adeno-associated virus and adenovirus vectors to develop inner-ear gene therapies targeting sensorineural hearing loss, which accounts for about 90 percent of hearing loss cases and affects more than 400 million people worldwide.

Committee member Francine Rogers pushed hard on whether the company's animal husbandry contractor, MISPRO, was adequately trained on the risks of handling cages after viral vector injections, saying she remained "concerned if they're going to be handling cage changes, et cetera, that they would need to be informed of the risks of your product." Approval was conditioned on risk assessment updates for sharps hazards and engineering controls, MISPRO contractor training documentation, and corrected emergency contact information — all to be submitted through the CitizenServe portal before the permit is issued.

In the full story:

• The complete report — 864 words

Source: the Other Committee meeting of April 16, 2026, reported from the official video recording and transcript.